Repligen’s (RGEN) Overweight Rating Reaffirmed at Stephens

Repligen (NASDAQ:RGEN)‘s stock had its “overweight” rating reaffirmed by research analysts at Stephens in a research report issued to clients and investors on Thursday, The Fly reports. They presently have a $110.00 target price on the biotechnology company’s stock. Stephens’ price target indicates a potential upside of 21.07% from the company’s current price.

A number of other brokerages have also weighed in on RGEN. ValuEngine lowered shares of Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 1st. BidaskClub raised shares of Repligen from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 27th. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 target price on shares of Repligen in a report on Monday, August 12th. Craig Hallum upped their target price on shares of Repligen from $80.00 to $108.00 and gave the company a “buy” rating in a report on Monday, August 5th. Finally, Zacks Investment Research cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $100.00.

Repligen stock traded down $1.80 during mid-day trading on Thursday, reaching $90.86. 376,892 shares of the company were exchanged, compared to its average volume of 700,947. The business has a fifty day moving average of $89.67 and a 200 day moving average of $71.41. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.88 and a current ratio of 2.25. The firm has a market cap of $4.81 billion, a P/E ratio of 124.47, a PEG ratio of 5.48 and a beta of 1.08. Repligen has a 12-month low of $48.26 and a 12-month high of $99.25.



Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. Repligen had a return on equity of 6.92% and a net margin of 11.42%. The company had revenue of $70.70 million during the quarter, compared to analyst estimates of $65.47 million. During the same quarter in the prior year, the business earned $0.14 earnings per share. Repligen’s revenue was up 48.1% on a year-over-year basis. Sell-side analysts predict that Repligen will post 0.97 EPS for the current year.

In related news, Director Karen A. Dawes sold 1,295 shares of the firm’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $77.35, for a total transaction of $100,168.25. Following the completion of the sale, the director now directly owns 118,329 shares of the company’s stock, valued at approximately $9,152,748.15. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.70% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Royce & Associates LP increased its position in Repligen by 40.6% during the first quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 145 shares during the period. Falcon Point Capital LLC lifted its stake in shares of Repligen by 2.5% in the first quarter. Falcon Point Capital LLC now owns 6,922 shares of the biotechnology company’s stock worth $409,000 after acquiring an additional 167 shares during the period. Arizona State Retirement System lifted its stake in shares of Repligen by 0.3% in the first quarter. Arizona State Retirement System now owns 60,301 shares of the biotechnology company’s stock worth $3,563,000 after acquiring an additional 188 shares during the period. Summit Creek Advisors LLC lifted its stake in shares of Repligen by 0.3% in the second quarter. Summit Creek Advisors LLC now owns 84,537 shares of the biotechnology company’s stock worth $7,266,000 after acquiring an additional 230 shares during the period. Finally, Pitcairn Co. lifted its stake in shares of Repligen by 7.0% in the second quarter. Pitcairn Co. now owns 3,769 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 245 shares during the period. 81.06% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Momentum Investing

The Fly

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.